Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Trial Profile

Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Burkitt's lymphoma; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARPALL
  • Most Recent Events

    • 13 Dec 2022 Results(n=12) assessing safety and biological efficacy of AUTO1/22 in a Phase I study in children young adults with relapsed and refractory Acute Lymphoblastic Leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2022 According to an Autolus media release, data from the trial will be presented at the American Society of Hematology (ASH) Annual Meeting 2022.
    • 17 Jun 2022 Results (n=10) assessing safety and biological efficacy of AUTO1/22 in relapsed/refractory acute lymphoblastic leukaemia, presented at the 27th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top